08.01.2013 - US-based Cubist Pharmaceuticals and British Heptares sealed a €7.2m license deal. Cubist pays to snatch a drug candidate for an undisclosed GPCR target.
The small spin-off Heptares Therapeutics from Welwyn Garden City north of London has landed a license deal with US biopharma Cubist Pharmaceuticals, Inc. Heptares’ area of expertise are G-protein coupled receptors (GPCR). Cubist will pay €4.2m up front and €3.1m in research funding plus undisclosed milestone payments and royalties. Heptares, in return, uses its proprietary platform technology to screen for drug candidates targeting an unnamed GPCR specified by Cubist. The deal also includes an option for a second target. Financial details covering that part of the collaboration have been predetermined – but will not be made public. Both parties agreed that the preclinical development will be carried out solely by Cubist.
Heptares was spun off from the Medical Research Council in 2007. The company engineers stabilised GPCRs (so-called STaRs), circumventing the problematic handling of the otherwise labile receptors. The UK firm entered biopharma main stage only last spring when it became eligible to receive payments potentially equalling €145m. Back then Irish Shire plc licensed a Heptares-discovered preclinical antagonist of the GPCR A2A (see photo) which could turn to a new CNS disorders medicine. Also AstraZeneca and Novartis belong to Heptares’ customers.
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more